Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Disease: Lessons and the Future
DOI:
https://doi.org/10.17140/IMOJ-4-113Keywords:
Diabetes mellitus (DM), Cardiovascular disease, Sodium-glucose cotransporter-2 inhibitors (SGLT2-I), Renal protectionAbstract
Diabetes mellitus (DM), an epidemic non-communicable disease, is associated with macro- and micro-vascular complications which may result in sudden cardiac death at a young age. Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) emerged as a new therapeutic option for managing DM with cardiovascular complications as well as diabetic patients with multiple risk factors. Three drugs in this class significantly reduced cardiovascular mortality and heart failure events, in both type 2 diabetes mellitus and non-diabetic patients with a reduced ejection fraction, to prevent heart failure related hospitalisation. Evidence of kidney protection was another major advantage provided in more than one study. We reviewed recent SGLT2-I related literature and discuss the benefits beyond the cardiac system.
References
De Simone G, Devereux RB, Chinali M, Lee ET, Galloway JM, Barac A, et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the strong heart study. J Hyper-tens. 2010; 28(2): 353-360. doi: 10.1097/HJH.0b013e3283331169
Redfield MM. Heart failure with preserved ejection fraction. N Engl J Med. 2016; 375(19): 1868-1877. doi: 10.1056/NEJM-cp1511175
Faden G, Faganello G, De Feo S, Berlinghieri N, Tarantini L, Di Lenarda A, et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mel-litus without overt cardiac disease: Data from the SHORTWAVE study. Diabetes Res Clin Pract. 2013; 101(3): 309-316. doi: 10.1016/j. diabres.2013.07.004
Boonman-de Winter LJ, Rutten FH, Cramer MJ, Landman MJ, Liem AH, Rutten GE, et al. High prevalence of previously un-known heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia. 2012; 55(8): 2154-2162. doi: 10.1007/s00125-012-2579-0
McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: A cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014; 2(10): 843-851. doi: 10.1016/S2213-8587(14)70031-2
Gilbert RE, Krum H. Heart failure in diabetes: Effects of anti-hyperglycaemic drug therapy. Lancet. 2015; 385(9982): 2107-2117. doi: 10.1016/S0140-6736(14)61402-1
Lynge TH, Svane J, Pedersen-Bjergaard U, Gislason G, Torp-Pedersen C, Banner J, et al. Sudden cardiac death among persons with diabetes aged 1-49 years: A 10-year nationwide study of 14 294 deaths in Denmark. Eur Heart J. 2020; 41(28): 2699-2706. doi: 10.1093/eurheartj/ehz891
Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017; 376(15): 1407-1418. doi: 10.1056/NEJMoa1608664
Cheng YJ, Imperatore G, Geiss LS, Saydah SH, Albright AL, Ali MK, et al. Trends and disparities in cardiovascular mortality among U.S. adults with and without self-reported diabetes, 1988-2015. Di-abetes Care. 2018; 41(11): 2306-2315. doi: 10.2337/dc18-0831
Pocock SJ, Ariti CA, McMurray JJ, Maggioni A, Køber L, Squire IB, et al. Predicting survival in heart failure: A risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013; 34(19): 1404-1413. doi: 10.1093/eurheartj/ehs337 Submit your article to this journal | https://openventio.org/submit-manuscript/ Mini Review | Volume 4 | Number 1| Kinsara AJA et al
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Han-tel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Eng J Med. 2015; 373(22): 2117-2128. doi: 10.1056/NEJMoa1504720
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017; 377(7): 644-657. doi: 10.1056/NEJMoa1611925
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 di-abetes. N Engl J Med. 2019; 380(4): 347-357. doi: 10.1056/NEJ-Moa1812389
Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: Why did EMPA-REG outcomes surprise and what were the likely mechanisms? Di-abetologia. 2016; 59(7): 1333-1339. doi: 10.1007/s00125-016-3956-x
Verma S, Jüni P, Mazer CD. Pump, pipes, and filter: do SGLT2 inhibitors cover it all? Lancet. 2019; 393(10166): 3-5. doi: 10.1016/ S0140-6736(18)32824-1
Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019; 139(22): 2528-2536. doi: 10.1161/CIRCULATIONAHA.119.040130
Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nether-cott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mel-litus: A meta-analysis of randomised controlled trials. Lancet. 2009; 373(9677): 1765-1772. doi: 10.1016/S0140-6736 (09) 60697-8
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in pa-tients with type 2 diabetes mellitus and previous myocardial infarc-tion. Circulation. 2019; 139(22): 2516-2527. doi: 10.1161/CIRCU-LATIONAHA.119.039996
Grant PJ, Cosentino F. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collabora-tion with the EASD: New features and the ‘Ten Commandments’ of the 2019 Guidelines are discussed by Professor Peter J. Grant and Professor Francesco Cosentino, the Task Force chairmen. Eur Heart J. 2019; 40(39): 3215-3217. doi: 10.1093/eurheartj/ehz687
Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mel-litus. Circulation. 2014; 129(5): 587-597. doi: 10.1161/CIRCULA-TIONAHA.113.005081
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Internal Medicine (IMOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.